

**Fig. 2: Top 20 Prescription Drugs by US Sales '13**

Rank	Product	Company	2013 Total (Billions)	2012 Total (Billions)
1	Abilify	Otsuka/BMS	\$6.6	\$5.7
2	Nexium	AstraZeneca	\$6.2	\$5.9
3	Humira	AbbVie	\$5.6	\$4.5
4	Crestor	AstraZeneca	\$5.4	\$5.0
5	Cymbalta	Eli Lilly	\$5.3	\$4.6
6	Advair Diskus	GlaxoSmithKline	\$5.2	\$4.8
7	Enbrel	Amgen	\$4.7	\$4.2
8	Remicade	Johnson & Johnson	\$4.1	\$3.8
9	Copaxone	Teva	\$3.7	\$3.5
10	Neulasta	Amgen	\$3.6	\$3.4
11	Rituxan	Genentech/Roche	\$3.3	\$3.1
12	Lantus SoloStar	Sanofi	\$3.0	\$2.2
13	Spiriva Handihaler	Boehringer Ingelheim	\$3.0	\$2.7
14	Atripla	BMS/Gilead	\$2.9	\$2.8
15	Januvia	Merck	\$2.9	\$2.6
16	Avastin	Genentech/Roche	\$2.7	\$2.6
17	Lantus	Sanofi	\$2.6	\$2.2
18	Oxycontin	Purdue	\$2.5	\$2.8
19	Lyrica	Pfizer	\$2.4	\$2.0
20	Epogen	Amgen	\$2.3	\$2.2
	<b>Total others</b>		<b>\$251.3</b>	<b>\$248.5</b>
	<b>Total market</b>		<b>\$329.2</b>	<b>\$319.1</b>

Source: IMS Health, National Sales Perspectives